EW
Edwards Lifesciences Corporation · Healthcare · Medical - Devices
Momentum inputs (comparable managers):
holder breadth -4.8% ·
share flow -2.9% ·
net new positions -5.0%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 14.87M | $1.28B | n/a | −2 |
| Q2 2026 | 163 | -6 | 423.46M | $38.23B | +2 | −9 |
| Q1 2026 | 173 | +2 | 408.99M | $32.75B | +6 | −5 |
| Q4 2025 | 170 | 0 | 441.50M | $37.63B | +2 | −1 |
| Q3 2025 | 24 | -1 | 280.60M | $21.82B | +1 | −3 |
| Q2 2025 | 23 | 0 | 232.09M | $18.15B | n/a | n/a |
| Q1 2025 | 20 | -1 | 112.98M | $8.18B | n/a | −1 |
| Q4 2024 | 21 | +1 | 116.40M | $8.61B | +1 | n/a |
| Q3 2024 | 19 | +1 | 77.58M | $5.12B | +2 | −1 |
| Q2 2024 | 18 | n/a | 60.09M | $5.55B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 29.13M | -12.3% | $2.11B | 0.4% | ▼ Trim | 4 | SEC ↗ ×9 |
| 2 | State Street Global Advisors ✦ (passive) | 25.78M | -0.1% | $1.87B | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 13.38M | +42.1% | $969.90M | 1.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | Geode Capital Management ✦ (passive) | 12.68M | -7.1% | $915.38M | 0.1% | ▼ Trim | 4 | SEC ↗ ×2 |
| 5 | Fisher Asset Management ✦ | 10.10M | +3.3% | $732.08M | 0.3% | ▲ Add | 4 | SEC ↗ |
| 6 | Norges Bank ✦ (passive) | 6.49M | -21.3% | $470.54M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 7 | Millennium Management ✦ | 3.44M | +1409.8% | $249.68M | 0.3% | ▲ Add | 4 | SEC ↗ |
| 8 | Marshall Wace ✦ | 3.03M | -47.9% | $219.66M | 0.3% | ▼ Trim | 4 | SEC ↗ ×3 |
| 9 | PRIMECAP Management ✦ | 2.30M | +12.5% | $166.68M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 10 | Point72 Asset Management ✦ | 1.47M | +149.7% | $106.45M | 0.3% | ▲ Add | 2 | SEC ↗ |
| 11 | Renaissance Technologies ✦ | 1.01M | +54.3% | $72.96M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 918.54K | +339.7% | $65.38M | 0.1% | ▲ Add | 4 | SEC ↗ ×6 |
| 13 | D. E. Shaw & Co. ✦ | 874.41K | -10.5% | $63.38M | 0.1% | ▼ Trim | 4 | SEC ↗ ×2 |
| 14 | T. Rowe Price ✦ | 859.69K | -73.9% | $62.31M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 15 | Baillie Gifford ✦ | 581.44K | -17.7% | $42.14M | 0.0% | ▼ Trim | 4 | SEC ↗ ×4 |
| 16 | Adage Capital Partners ✦ | 453.27K | -63.0% | $32.85M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 17 | Arrowstreet Capital ✦ | 266.06K | +478.5% | $19.28M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | Two Sigma Investments ✦ | 97.10K | -22.3% | $7.04M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 19 | Bridgewater Associates ✦ | 62.52K | -42.3% | $4.53M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 20 | Gotham Asset Management ✦ | 43.66K | +165.8% | $3.16M | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Soros Fund Management | $18.51M | was 0.5% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 4 holders, 229.24K shares, $319,498 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 619 sh · $53,017
Officer · 619 sh · $54,169
Officer · 544 sh · $49,534
Officer · 2.64K sh · $237,907
Officer · 1.24K sh · $113,417
Officer · 1.15K sh · $105,893
Officer · 30.65K sh · $2.79M
Officer · 619 sh · $56,967
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology